NCT05687422

Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

Status unknown NA Last updated 18 January 2023

What this trial tests

NA trial testing 100μm laser spot diameter micropulse laser in Central Serous Chorioretinopathy in 50 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Beijing Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	1 February 2023
Primary completion	31 December 2023
Estimated completion	31 December 2023

Drugs / interventions tested

• 100μm laser spot diameter micropulse laser
• 200μm laser spot diameter micropulse laser

Conditions studied

• Central Serous Chorioretinopathy — all drugs for Central Serous Chorioretinopathy →

Sponsor

Beijing Hospital

Who can join

Adults 18 to 50, any sex, with Central Serous Chorioretinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in treating chronic CSC is proved to be safe and effective. However, some studies indicate that it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including us, think that this may be related to micropulse laser parameters. Thus we need to explore better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to compare the treatment effect of two different patterns of laser parameters (small and regular spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial, by comparing the subretinal fluid regression ratio, central retinal thickness, macular microvisual field, macular vascular density, chroidal volume changes and visual acuity of two groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy of refined micropulse laser in treating chronic CSC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Three-dimensional choroidal characteristics in different subtypes of central serous chorioretinopathy using swept-source optical coherence tomography angiography.
   Zhang Y, Wang J, Liu J, Gu X, et al · · 2025 · PMID 39557692 · DOI 10.1007/s00417-024-06691-8